-
Wuxi Biologics Set to Be Removed from US Restricted Trade List
•
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US Department of Commerce restricted trade list, a development first reported in February this year. This news has significantly boosted the firm’s valuation, wiping away HKD 77 billion (USD 9.9 billion) in losses. Chinese authorities permitted…
-
CDE Releases 60th Batch of Chemical Generic Reference Preparations
•
The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference preparations, adding 93 new specifications. The public feedback deadline for this batch is July 18, 2022. Batch DetailsIn this batch, 49 specifications had their information updated. However, 16 specifications failed the review process due to…
-
Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies
•
China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD 20.9 million) in an angel financing round. The round was led by Emerging Technology Partners (ETP) and Redhill Capital, with contributions from CASI Pharmaceuticals Inc. (NASDAQ: CASI). The proceeds will be used for a clinical…
-
Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development
•
China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million) in a pre-Series C financing round led by Wuhan Hi-Tech, Hubei Science Technology Investment, and Optics Valley Financial Holding. The proceeds will be used for the clinical development of bispecific antibodies (BsAbs) and COVID-19 vaccines,…
-
Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM
•
China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Science (CAMS) regarding LXH-2201. LXH-2201 is a Category 1 drug being developed to treat cardiovascular diseases and has completed both pre-clinical and Phase…
-
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
•
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for its oral antiviral drug S-217622, developed through a joint venture with Ping An Life Insurance Company under the name Ping An-Shionogi Co., Ltd. Drug ProfileS-217622 is an oral…
-
InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
•
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its targeted protein degrader ICP-490. The drug is approved for use in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and other hematological malignancies. Drug ProfileICP-490, developed through InnoCare’s molecular glue…
-
Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
•
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA – targeted chimeric antigen receptor (CAR) T cell therapy and Novartis’ Zolgensma (OAV101) have been awarded breakthrough therapy designations (BTDs). Hrain Bio’s BCMA CAR – T cell is indicated for relapsed / refractory multiple myeloma. The…
